pre-IPO PHARMA

COMPANY OVERVIEW

Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response.


LOCATION

  • San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.tempesttx.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    eight-roads-ventures f-prime-capital-partners foresite-capital inception lilly-asia-ventures quan-capital versant-ventures


    PRESS RELEASES


    Jul 12, 2021

    Thinking about buying stock in Tempest Therapeutics, Cemtrex, Exela Technologies, Aethlon Medical, or Bridgeline Digital?


    May 16, 2019

    Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist


    Nov 13, 2018

    Tempest Therapeutics Reports Proof of Mechanism Data for First-in-Class PPAR Alpha Antagonist


    Sep 4, 2018

    Tempest Therapeutics Names Dr. Ginna Laport CMO


    Mar 28, 2018

    Tempest Therapeutics Closes $70 Million Series B Financing


    For More Press Releases


    Google Analytics Alternative